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Abstract
Introduction. Arterial hypertension (AH) is a  well-known cardiovascular risk factor. Currently, in Poland, 
approximately 32% of adults suffer from AH, and only 26% of them are treated successfully. The study aims 
to determine the incidence of atherosclerosis risk factors and their influence on the effectiveness of hypotensive 
treatment in the population of patients with AH and coexisting coronary artery disease (CAD) or coronary 
equivalent.
Material and methods. The study included 204 adults. The inclusion criteria were: diagnosis of AH with coexisting 
a diagnosis of CAD (138 people) or coronary equivalent defined as high (≥ 5%) atherosclerosis-related risk of death 
in 10-year prognosis, estimated using the EURO SCORE scale (66 people). During observation, pharmacological 
and nonpharmacological treatments were modified according to the current AH treating standards. After 6 months 
of observation, the effectiveness of AH control was assessed. 
Results. Multivariate logistic regression analysis revealed that main factors affecting poor blood pressure control 
after six months of observation were: obesity, age > 65 years, LDL cholesterol level > 130 mg/dL. Moreover, systolic 
blood pressure (SBP) < 140 mmHg was more frequent in patients with diabetes mellitus. After six months of the-
rapy, good control of SBP was found in 42.7% of patients and normal values of diastolic blood pressure (DBP) — in 
65.2 % of patients.
Conclusion. Independent risk factors for poor control of blood pressure were: high level of LDL-cholesterol, age 
> 65 years and female sex. Paradoxically, diabetes was not a risk factor for poor control of hypertension. The intro-
duction of combined hypotensive and lipid-lowering drugs should contribute to a better control of hypertension 
in Poland.
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Streszczenie
Wstęp. Nadciśnienie tętnicze (AH) jest uznanym czynnikiem ryzyka schorzeń układu sercowo-naczyniowego. Obec-
nie 32% Polaków ma stwierdzone nadciśnienie tętnicze, z czego tylko 26% jest skutecznie leczonych. Celem pracy było 
określenie częstości występowania czynników ryzyka miażdżycy i ich wpływu na skuteczność leczenia hipotensyjnego 
w populacji pacjentów z AH i współistniejącą chorobą niedokrwienną serca (CAD) lub ekwiwalentem wieńcowym.
Materiał i  metody. Kryterium włączenia do badania dla 204 osób stanowiło rozpoznanie HA (204 osoby), 
rozpoznanie CAD (138 osób) lub obecność ekwiwalentu wieńcowego rozumianego jako wysokie (≥ 5%) ryzyko 
zgonu z powodu miażdżycy w ciągu najbliższych 10 lat, szacowane według skali oceny ryzyka SCORE (66 osób). 
W czasie obserwacji modyfikowano postępowanie niefarmakologiczne i farmakologiczne zgodnie z obowiązującymi 
standardami leczenia AH, ponownie oceniając uzyskaną skuteczność kontroli AH po 6 miesiącach.
Wyniki. Analiza wieloczynnikowa wykazała, że niezależnymi czynnikami wpływającymi na brak prawidłowej kon-
troli wartości ciśnienia tętniczego po 6 miesiącach były: otyłość, wiek > 65 lat, stężenie cholesterolu frakcji LDL 
> 130 mg/dl. Wykazano również, że pacjenci z cukrzycą łatwiej osiągali wartości skurczowego ciśnienia tętniczego 
(SBP) < 140 mm Hg. Po 6 miesiącach terapii zadowalającą kontrolę SBP odnotowano u 42,7%, a rozkurczowego 
ciśnienia tętniczego u 65,2% pacjentów.
Wnioski. Niezależnymi czynnikami ryzyka braku prawidłowej kontroli wartości ciśnienia tętniczego były: pod-
wyższone stężenia cholesterolu frakcji LDL, otyłość, wiek > 65 lat i płeć żeńska. Paradoksalnie, cukrzyca nie była 
czynnikiem zwiększającym ryzyko nieprawidłowej kontroli wartości ciśnienia tętniczego. Wprowadzenie skoja-
rzonych preparatów hipotensyjno-hipolipemizujących powinno w szczególny sposób przyczynić się do lepszej kon-
troli nadciśnienia tętniczego w Polsce.
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Background
Arterial hypertension (AH) is a confirmed risk fac-
tor of cardiovascular diseases. Effective hypotensive 
therapy reduces morbidity and mortality associated 
with this disease [1]. 
Based on the results of NATPOL 2011 and POL-
SENIOR trials, it was found that the number of 
adult Poles between 18 and 79 years old suffering 
from arterial hypertension was 9.8 million (32% of 
the overall population; 36.8% of the male popula-
tion, 29.4% of the female population). This value 
reaches 34% when people over 80 years old are in-
cluded (about 1 million people) [2, 3].
Due to increased awareness of the harmful effect 
of AH, the percentage of treated people is increas-
ing systematically. Moreover, the number of patients 
who are aware of the presence of the disease is also 
increasing (change from 66% in 2002 to 72% in 
2011). Unfortunately, 3.1 million people still do not 
know that they have AH, which may be due to the 
fact that 40% of Poles do not know their blood pres-
sure values. Nevertheless, it seems beneficial that the 
proportion of successfully treated people increased 
from 12% (NATPOL PLUS 2002) to 26% in 2011 
(NATPOL 2011) [2]. The prevalence of arterial hy-
pertension in Poland is comparable to some European 
countries (Czech Republic, Romania, Portugal) and 
5–10% higher than in Turkey and Italy. In 2011 the 
prevalence of arterial hypertension in Poland was 
4.5% higher than in the Unites States of America 
and the proportion of successfully treated patients 
was 2 times lower [2]. It may be related to more 
frequent use of modern pharmacotherapy, including 
combined hypotensive drugs in these countries.
Coronary artery disease, first of all including myo-
cardial infarction, is the leading cause of cardiovas-
cular death and the first cause of death in Europe 
among people under 75 years old and is responsible 
for 12.9% of total DALY (disability adjusted life-
years) [4].
The aim of the study was to attempt to identify 
interactions and correlations between effective hy-
potensive therapy and cardiovascular risk factors in 
patients with coexisting arterial hypertension and 
coronary artery disease (or coronary equivalent) un-
der the care of a specialist cardiologist. 
Material and methods
The study cohort consisted of 204 consecutive 
adult patients with AH (mean age of the study 
population was 64.4 years) under the care of the Car-
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Table I. Basic clinical parameters of the study group
Parameter n = 204
Sex (female) 118 (58)
Abdominal obesity 186 (91)
Metabolic syndrome (according to IDF) 172 (84.5)
Abnormal weight 127 (62)
Obesity 48 (23.5)
Dyslipidaemia 112 (55) to 88 (43)
Diabetes mellitus 68 (33.5)
Impaired carbohydrate metabolism 118 (58)
Chronic kidney disease GFR <90 mL/min 128 (62.5)
Data are presented as number (percentage) of examined patients. GFR — 
glomerular filtration rate; IDF — International Diabetes Federation
Figure 1. Risk of inappropriate systolic blood pressure control (after 
6 month of treatment) depending on number of risk factors for poor 
control of blood pressure values (n = 33). Interpretation of the 
graph. Independent risk factors for poor control of blood pressure 
values were: obesity, age >65 years, high level of LDL cholesterol 
and absence of diabetes. The graph presents the relative risk of in-
appropriate systolic blood pressure control depending on the preva-
lence of: 0, 1, 2, 3 and 4 variables evaluated in the model presented 
in Table III. The highest risk of poor antihypertensive control was 
observed in patients aged > 65 years, with LDL-C > 130 mg/ 
/dL, without diabetes (bar 4). BMI — Body Mass Index; LDL-C — 
LDL cholesterol; N — number of patients; SBP — systolic blood 
pressure
diologic Outpatients’ Ambulatory Clinic in Gorzów 
Wielkopolski in the first decade of 21st century. In-
clusion criteria were: 1) diagnosis of AH, coexisting 
with: 2) diagnosis of coronary artery disease (CAD) 
(138 patients); and/or 3) the presence of coronary 
equivalent, defined as high (≥ 5%) risk of death from 
atherosclerosis in the next 10 years, estimated accord-
ing to the EURO SCORE scale (66 patients). The 
primary clinical parameters for the study group are 
listed in Table I. Depending on the value of systolic 
blood pressure (SBP) and diastolic blood pressure 
(DBP) the patients were assigned to different sub-
groups of AH control, i.e. subgroups with normal 
(< 140 mmHg for SBP and/or < 90 mmHg for DBP) 
and abnormal blood pressure control (≥ 140 mmHg 
for SBP and/or ≥ 90 mmHg for DBP). During ob-
servation, non-pharmacological and pharmacological 
managements were modified according to the cur-
rent guidelines for arterial hypertension diagnosis and 
management, increasing drug doses and implement-
ing further hypotensive drugs. The efficacy of AH 
control was evaluated after 6-month therapy. 
Data on age, sex, body mass index (BMI), cig-
arette smoking and the presence of diabetes melli-
tus were analysed. Among the results of laboratory 
tests, serum levels of triglycerides, total cholesterol, 
HDL-C, LDL-C and creatinine clearance were ana-
lysed. The data on coronary artery disease were also 
analysed: the previous diagnosis of coronary artery 
disease and pharmacotherapy.
Statistical analysis
The effect of selected factors on the analysed end-
point — effectiveness of blood pressure control — 
was investigated using a multivariate logistic regres-
sion model [5]. The analysis was performed by the 
stepwise elimination method, assuming the level of 
0.1 to remain in the model and setting a threshold 
for statistically significant differences at 5%.
The predictive value of the final model was as-
sessed with the use of ROC curves (so-called C statis-
tics). Model’s goodness of fit was checked by Pearson 
or Hosmer-Lemeshow tests. Good fit of the prog-
nostic model for complications is a lack of statistical 
significance in the Pearson or Hosmer-Lemeshow 
tests. Statistical calculations were performed using 
licensed SAS and Excel programs.
Results
LDL-C elevation > 130 mg/dL, obesity, age > 65 
years and female sex were found as important pre-
dictors for the risk of ineffective hypotensive therapy 
in the set of analysed features at the time point „after 
6-month therapy”. Paradoxically, diabetes mellitus 
was not a factor that increased the risk of poor con-
trol of blood pressure (Figure 1, Table II).
After 6 months of treatment, 42.7% of patients 
were in the normal (< 140 mmHg) SBP group. The 
number of people with normal (< 90 mmHg) DBP 
values was significantly higher, accounting for 65.2% 
of the study population.
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Table II. Risk of poor control of systolic blood pressure value — 
assessment after 6-month therapy
N = 33 OR (95% CI) P
Age > 65 years 2.88 (1.18–7.02) 0.020
Male sex > 0.1
Weight > 81 kg > 0.1
Overweight (BMI 25–29.9 kg/m2) > 0.1
Obesity (BMI ≥ 30 kg/m2) 7.13 (2.68–19.00) < 0.001
Smoking > 0.1
Diabetes mellitus 0.34 (0.13–0.91) 0.033
Coronary artery disease (CAD) > 0.1
Triglycerides > 150 mg/dL > 0.1
Cholesterol > 200 mg/dL > 0.1
LDL-C > 130 mg/dL 2.66 (1.13–6.23) 0.024
HDL-C < 40 mg/dL > 0.1
Creatinine clearance > 0.1
Acetylsalicylic acid > 75 mg/day > 0.1
BMI — Body Mass Index; N — number of patients; OR — odds ratio; p — level of statistical signifi-
cance; 95% Cl — 95-confidence interval
Table III. The odds ratio of the risk of poor blood pressure control 
for: systolic blood pressure (SBP), diastolic blood pressure (DBP), 
SBP and/or DBP, SBP and DBP
Parameter SBP DBP SBP  
and/or DBP
SBP  
and DBP
Age > 65 years 2.88 2.05
BMI ≥ 30 kg/m2 7.13 16.54
Diabetes mellitus 0.34 0.19 0.29 0.14
LDL-C > 130 mg/dL 2.66 6.77 5.96 12.84
Male sex 0.26 0.29
BMI 25–29.9 kg/m2 0.07
Weight > 81 kg 5.96
BMI — Body Mass Index; DBP — diastolic blood pressure; SBP — systolic blood pressure
Discussion
From the analysis of the data in Table III, it can be 
concluded that only two factors have been predictors 
of insufficient blood pressure control after 6 months of 
treatment in all 4 models. These were: absence of dia-
betes and baseline LDL cholesterol level > 130 mg/dL. 
The baseline LDL-C abnormalities are associated 
with worse prognosis as to the effectiveness of the im-
plemented and intensified therapy during 6 months of 
hypotensive therapy. The presence of diabetes, as not-
ed in this study, paradoxically was associated with bet-
ter antihypertensive control after 6 months of therapy. 
This may suggests that patients with diabetes, CAD 
and AH are treated more aggressively and more opti-
mally so they are more likely to achieve normal blood 
pressure values. According to the current guidelines 
of the Polish Society of Hypertension, the presence 
of diabetes is an indication for the implementation of 
a statin and hypotensive therapy in any case of hyper-
tension [1]. 
Recent studies showed that patients with prediabe-
tes may benefit from the combination of a statin and 
antihypertensive therapy. Chinese researchers (Huang 
et al.) have analysed the efficacy of atorvastatin and 
amlodipine combination in patients with prediabetes.
Forty-five consecutive patients with hypertension 
were divided into two groups based on the presence 
(HD group, n D 23) or absence (H group, n D 22) 
of prediabetes. All patients underwent 12-week treat-
ment with daily single-pill amlodipine/atorvastatin 
combination. This treatment significantly reduced 
(p < 0.01) BP and blood lipid levels in H and HD 
groups to a statistically similar extent (p > 0.05). In 
the HD and H groups there were significantly (all 
p-values < 0.01) lower levels of markers of inflamma-
tion (ICAM-1 and TNF-a) with more pronounced 
reductions in patients with prediabetes. ICAM-1 lev-
el significantly (p < 0.01) decreased by 14.44% in the 
H group (from 3.81 ± 0.60 pg/mL to 3.26 ± 0.32 pg/ 
/mL) and by 24.82% in the HD group (from 4.07 
± 0.70 pg/mL to 3.06 ± 0.34 pg/mL). TNF-a level 
also significantly (p < 0.01) decreased after treatment 
by 20.47% in the H group (from 101.79 ± 11.72 pg/ 
/mL to 80.95 ± 9.33 pg/mL) and by 29.05% in the 
HD group (from 110.94 ± 10.71 pg/mL to 78.71 ± 
9.19 pg/mL) [6].
Beta-blockers and ACE-inhibitors are recom-
mended in patients with coronary artery disease 
and in cases of angina — calcium channel blockers 
(CCBs) are preferred [1]. Equally important is statin 
therapy in this group of patients.
Numerous publications report the pleiotropic ef-
fect of statins, such as improvement of endothelial 
function, enhancing the stability of atherosclerotic 
plaques, decreasing oxidative stress and inflamma-
tion, inhibiting vasoconstriction, stimulating and 
upregulating endothelial NO synthase (eNOS) [7]. 
Statins can reduce the hardening of the arteries, im-
prove arterial compliance, improve left ventricular 
hypertrophy and inhibit cell proliferation by reduc-
ing angiotensin I [8]. 
Several lines of research indicate that statins can 
lower blood pressure (BP) independently of their 
lipid-lowering effects when used as monotherapy and 
in combination with antihypertensive agents. The 
PERSPECTIVA study performed in 2017 recruited 
587 adults with untreated or uncontrolled hyperten-
sion and hypercholesterolaemia. All patients received 
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treatment with single-pill combination perindopril/ 
/amlodipine. Additionally, 226 patients in this group 
received the statin. During the 60-day follow-up, 
a  better control of blood pressure was observed in 
statin [+] group (73% vs. 64%, p < 0.05) [9].
It has also been proven that combined treatment 
with a statin and a calcium channel blocker are more 
effective in reducing cardiovascular risk than each 
of these drugs used alone. This is due to the fact 
that these drugs have not only lipid-lowering and 
antihypertensive properties but also could increase 
the level of tissue plasminogen activator, increase 
compliance of small artery walls, and decrease insu-
lin resistance [10].
Equally interesting are the findings from the Eu-
ropean ALL-IN-ONE study. A total of 305 hyper-
tensive patients were randomised 1:1. The “fixed 
group” (154 of patients) was given a once-daily fixed 
combination (ODFC) of perindopril 10 mg plus 
indapamide 2.5 mg plus amlodipine 5 or 10 mg 
plus atorvastatin 20 mg. The “free group” was given 
a free-drug combination (FDC) of the three antihy-
pertensive agents plus atorvastatin 20 mg at the free 
time in the day. At 12-weeks, the fixed group had 
lower systolic BP (124.46 ± 6.4 vs. 129.02 ± 5.03 
mmHg, p = 0.002) and similar diastolic BP (81.24 
± 3.4 vs. 83.09 ± 3.1 mmHg, p = 0.082) compared 
to the free group. BP targets at week 12 were more 
commonly reached with fixed than free combination 
(89% and 80% respectively, p = 0.048). For CV risk 
in both groups there was a  significant reduction; 
however, CV risk reduction was greater in those 
taking ODF combination (fixed group — 38.5%; 
free group — 35.4%). Compliance was significantly 
greater in the fixed group vs. the free group (94% vs. 
85% respectively, p = 0.034). There were no statisti-
cally significant differences between diastolic blood 
pressure, LDL-C level and adverse events [11].
A meta-analysis conducted by Bertrand et al. in 
August 2014 showed that administration of a combi-
nation of two antihypertensive agents and lipid-low-
ering therapy, such as an ACE inhibitor, a  CCB, 
and a statin, in a single-pill formulation reduced the 
risk of myocardial infarction, sudden cardiac death 
and cardiovascular death by 46%. Furthermore, sin-
gle-pill formulations (“polypill”) are known to result 
in better adherence to the treatment [12, 13].
Study limitation
Presented study was conducted in the first decade of 
the 21st century in Gorzów Wielkopolski. Based on 
the results of this study, the doctoral dissertation was 
created, graduated in 2007 at Medical University of 
Warsaw [14]. It has been decided now to report its 
results after a decade due to the special validity of its 
conclusions.
Independent factors of poor hypotensive control 
were elevated LDL-C levels, which suggests the pos-
sibility of addressing this therapeutic problem using 
combined hypotensive-hypolipaemic drugs (ator-
vastatin + amlodipine; rosuvastatin + amlodipine; 
rosuvastatin + valsartan) or special triple drug com-
bination (atorvastatin + perindopril + amlodipine) 
currently available and newly introduced onto the 
Polish pharmaceutical market. Conclusions of pre-
sented study are interesting after a  decade in the 
context of too rare use of these drugs in nowadays 
clinical practice in our country [15, 16].
Conclusions
1. Independent risk factors of poor hypotensive 
control were: elevated LDL-C levels, obesity, age 
> 65 years and female sex. Paradoxically, diabetes 
mellitus was not a factor increasing a risk of poor 
hypotensive control. 
2. In the study population diagnosis of coronary artery 
disease and kidney function impairment was not as-
sociated with a worse effect of hypotensive treatment.
3. Newly introduced combined hypotensive and 
lipid-lowering drugs should contribute to better 
control of arterial hypertension in Poland.
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